Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo)

Ward R.; Ashton S.; Bianco A.; Colclough N.; Cross D.; Cuomo E.; Finlay M. R. V.; Floch N.; Fitzek M.; Martin M.; Menard L.; McKerrecher D.; ONeill D.; Orme J.; Talbot V.; Staniszewska A.; Yates J.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo)

【24h】

Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo)

机译：Osimertinib（AZD9291），不可逆的第三代TKI，在具有最普遍的EGFR Ex20Ins的NSCLC临床前模型中（体外和体内）诱导肿瘤生长抑制

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共1页
作者
Ward R.; Ashton S.; Bianco A.; Colclough N.; Cross D.; Cuomo E.; Finlay M. R. V.; Floch N.; Fitzek M.; Martin M.; Menard L.; McKerrecher D.; ONeill D.; Orme J.; Talbot V.; Staniszewska A.; Yates J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo) [J] . Ward R., Ashton S., Bianco A., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：Osimertinib（AZD9291），不可逆的第三代TKI，在具有最普遍的EGFR Ex20Ins的NSCLC临床前模型中（体外和体内）诱导肿瘤生长抑制
2. Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs [J] . Colclough N., Ballard P. G., Barton P., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：奥西替尼（AZD9291）与其他不可逆的下一代EGFR TKIs的血脑屏障（BBB）通透性的临床前比较
3. Preclinical comparison of the blood brain barrier (BBB) permeability of osimertinib (AZD9291) with other irreversible next generation EGFR TKIs [J] . Colclough N., Ballard P. G., Barton P., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：Esimertinib（AZD9291）与其他不可逆的下一代EGFR TKIS的血脑屏障（BBB）渗透性的临床前比较
4. The C-terminal decapeptide of prothymosin alpha induces a TH1-type immune response in vitro and retards tumor growth in vivo. [C] . Ioannou K., Samara P., Kavrochorianou N., Joint Conferences of the International Cytokine Society and the International Society for Interferon and Cytokine Research . 2011

机译：胰蛋白酶磷酸氨酰α的C末端抑制肽在体外诱导Th1型免疫应答，并在体内延缓肿瘤生长。
5. Modeling the consequences of epidermal growth factor receptor inhibition in vivo using the classical EGFR⟨wa2⟩ mutant mouse. [D] . Roberts, Reade Bruce. 2003

机译：使用经典的EGFR〈wa2〉突变小鼠对体内表皮生长因子受体抑制的后果进行建模。
6. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC [O] . Silvia La Monica, Roberta Minari, Daniele Cretella, 2019

机译：第三代EGFR抑制剂osimertinib联合培美曲塞或顺铂在EGFR突变的非小细胞肺癌临床前模型中发挥持久的抗肿瘤作用
7. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions [O] . Nicolas Floch, Matthew J. Martin, Jonathan W. Riess, 2018

机译：Osimertinib的抗肿瘤活性，一种不可逆突变体选择性EGFR酪氨酸激酶抑制剂，NSCLC含有EGFR外显子20插入

Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo)

著录项

相似文献

相关主题

期刊订阅